X

Prostate Cancer

Prostate Cancer

Addition of AKT Inhibitor Ipatasertib to Abiraterone/Prednisolone in mCRPC With PTEN Loss

Study investigators find that the addition of the AKT inhibitor ipatasertib to abiraterone and prednisolone produces a significant improvement in PFS among patients with mCRPC with PTEN loss...

The ASCO Post
07/21/2021
VISION Trial: Novel PSMA-Targeted Radiotherapy Improves Outcomes in Metastatic Prostate Cancer

LuPSMA significantly improved radiographic PFS and OS when added to the standard of care compared with the standard of care alone for men with mCRPC who had experienced...

The ASCO Post
07/13/2021

MRI Plus New Score Halves Biopsy Rate for Prostate Cancer

Swapping traditional prostate biopsies for MRI-targeted biopsies with a new prostate cancer risk score can cut the number of unnecessary biopsies in half while still detecting...

Medscape
07/09/2021
Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer

Although docetaxel is not recommended when managing men with unfavorable-risk prostate cancer given negative or inconclusive results from previous randomized trials, unstudied benefits may exist.

Journal of Clinical Oncology
07/01/2021
Targeted Radiotherapy Improves Survival in Metastatic Prostate Cancer

An investigational targeted RT significantly improves radiographic PFS and prolongs OS compared to standard of care therapy in men with advanced-stage mCRPC.

Oncology Times - Latest Articles
07/05/2021
Lu-177–PSMA-617 Radioligand Therapy Prolongs Survival When Added to Standard of Care in Metastatic Castration-Resistant Prostate Cancer

The phase III VISION trial has shown prolonged PFS and OS with lutetium-177–PSMA-617 radioligand therapy plus standard care vs standard care alone in previously treated mCRPC.

The ASCO Post
06/28/2021
All-Cause Mortality Risk With Adjuvant vs Early Salvage Radiotherapy After Radical Prostatectomy

Tilki et al find that adjuvant RT is associated with reduced risk for all-cause mortality vs early salvage radiotherapy among men at high risk for disease recurrence following radical prostatectomy

The ASCO Post
06/16/2021
HGK Promotes Metastatic Dissemination in Prostate Cancer

In this study, investigators identify MAP4K4 as a relevant gene for metastasis in prostate cancer.

Scientific Reports
06/10/2021
Integration of Circulating Tumor Cell and Neutrophil-Lymphocyte Ratio to Identify High-Risk Metastatic Castration-Resistant Prostate Cancer Patients

 

The neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and circulating tumor cells have been associated with survival in castration-resistant prostate cancer.

BMC Cancer
06/02/2021
Diversity of Epithelial-Mesenchymal Phenotypes in Circulating Tumour Cells from Prostate Cancer Patient-Derived Xenograft Models

The aim of this study is to molecularly characterise CTCs in a panel of prostate cancer patient-derived xenografts using genes associated with epithelial and mesenchymal phenotypes...

Cancers
06/01/2021
Prostate Cancer Risk Variants of the HOXB Genetic Locus

Study investigators examine the HOXB locus to define a potentially broader contribution to prostate cancer heritability.

Scientific Reports
05/31/2021
Ultrasound Therapy, Chemotherapy and Their Combination for Prostate Cancer

Prostate cancer's current treatment includes various physical and chemical approaches for the localized and advanced prostate cancer (e.g. mCRPC).

05/20/2021
Normal Basal Epithelial Cells Stimulate the Migration and Invasion of Prostate Cancer Cell RM-1 by TGF-β1/STAT3 Axis in vitro

This study aims to investigate whether basal epithelial cells could suppress migration and invasion of prostate cancer cells to become a new treatment strategy for prostate cancer.

Cancer Management and Research
05/07/2021
Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From “All-Comers” to “Personalized” Approach

A remarkable evolution in the treatment of mCSPC has been noted in the previous several years.

OncoTargets and Therapy
05/05/2021
Silencing of PSMC2 Inhibits Development and Metastasis of Prostate Cancer Through Regulating Proliferation, Apoptosis and Migration

Here, expression of PSMC2 in tumor tissues or cells of prostate cancer is detected by qPCR, western blotting and immunohistochemical analysis.

Cancer Cell International
04/26/2021
Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies

The purpose of this study is to evaluate the impact of time to castration resistance in mHSPC patients on overall survival in the era of combination therapies for mHSPC.

Frontiers in Oncology
04/23/2021
Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer

This study investigates whether grouping genomic alterations with other events within the same cellular pathways would offer increased precision for biomarker discovery. 

Cancers
03/30/2021
Prostate Cancer and PARP Inhibitors: Progress and Challenges

In solid tumors, the first demonstration of an improvement in overall survival is provided by olaparib in patients with mCRPC harboring homologous recombination repair deficiencies.

Journal of Hematology & Oncology
03/29/2021
Distinct DNA Methylation Patterns Associated With Treatment Resistance in Metastatic Castration Resistant Prostate Cancer

Investigating the dynamics of the methylation changes going from the castration sensitive to the tNEPC state would provide insights into novel mechanisms of resistance. 

Scientific Reports
03/23/2021
Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation

Study investigators demonstrate that in hormonal sensitive human prostate cancer cells the combination therapy of Abiraterone plus Enzalutamide reduced cell growth and survival. 

Cancers
03/23/2021
LuPSMA Outperforms Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer in Phase II Trial

Following disease progression on docetaxel, PSMA-targeted radionuclide therapy reduces the risk of disease progression or death by 37% vs cabazitaxel in men with mCRPC...

The ASCO Post
03/25/2021
Can Treatment for Prostate Cancer Affect Smell and Taste?

One in six men being treated for advanced prostate cancer reported experiencing a reduced sense of smell and taste, according to a study published by Alonzi et al. 

The ASCO Post
03/17/2021
Radiotherapy of Oligometastatic Prostate Cancer

Due to improved imaging sensitivity, the term “oligometastatic” prostate cancer disease is diagnosed more often, leading to an increasing interest in metastasis-directed therapy.

Radiation Oncology
03/09/2021
Cell-Free DNA Concentration and Fragment Size as a Biomarker for Prostate Cancer

This study investigates whether differences in cfDNA concentration and cfDNA fragment size could improve the sensitivity for detecting more advanced and aggressive prostate cancer.

Scientific Reports
03/03/2021
Effect of Prior Cancer on Survival Outcomes for Patients With Advanced Prostate Cancer

Whether a prior cancer history has an adversely impact on clinical outcomes for patients with advanced prostate cancer remains largely unknown.

BMC Urology
02/17/2021
Identification of Lipidomic Profiles Associated With Drug-Resistant Prostate Cancer Cells

The association of circulating lipids with clinical outcomes of drug-resistant castration-resistant prostate cancer is not fully understood.

Lipids in Health and Disease
02/17/2021
Liquid vs Tissue Biopsy in Prostate Cancer: Why Not Both?

The genomic landscape of circulating tumor DNA was comparable to the landscape of tissue biopsies in a large study of patients with metastatic castration-resistant prostate cancer. 

Medscape
02/15/2021
The Expression of YWHAZ and NDRG1 Predicts Aggressive Outcome in Human Prostate Cancer

This study aims to identify molecular biomarkers that could improve risk prediction in prostate cancer.

01/22/2021
Establishment and Validation of a Novel Predictive Model to Quantify the Risk of Bone Metastasis in Patients With Prostate Cancer

This study aims to construct and validate a nomogram to quantify bone metastasis risk in patients with prostate cancer. 

01/20/2021
Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer

This study seeks to answer the question surrounding the most effective systemic treatments for metastatic castration-sensitive prostate cancer.

JAMA Oncology
01/14/2021
18F-Guided PET Radiotracing Boosts Survival After Prostate Cancer Relapse

Adding the 18F-fluciclovine PET radiotracer to help guide radiation treatments for recurrent prostate cancer can improve disease-free survival rates, results from a Phase III study show.

Oncology Times - Latest Articles
12/05/2020
Reducing Immunotherapy Resistance in Prostate Tumors

Reprogramming immune cells inside tissues surrounding prostate tumors may improve response to CPI therapy in patients, according to a new study by researchers...

Oncology Times - Latest Articles
07/05/2021

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834